ライフサイエンスコーパス: BMD

1 BMD at other sites was assessed in single trials: calciu

2 BMD recovery offers an increased quality of life for peo

3 BMD was calculated for all three approaches and compared

4 BMD was not different across quartiles of protein intake

5 BMD, fat mass and lean mass were collected from Dual-ene

6 Meanwhile 107 BMD-associated genes from people of European descent wer

7 oters in open chromatin for ~ 17% of the 273 BMD loci investigated.

8 e (n = 31,800) and femoral neck (n = 32,961) BMD, and from the arcOGEN consortium for three OA phenot

9 ay detect B. miyamotoi in the blood of acute BMD patients, we made standard malariological thick smea

10 ere decreased in the turkey ceca early after BMD administration.

11 HU resulted in lower BMC and BMD in total femur, and lower BV/TV in distal femur and

12 ctory had 3.2-3.4% higher total body BMC and BMD than those who were in the "consistently lower" traj

13 h the imaging and quantification of bone and BMD.

14 For cefoxitin DD and BMD results interpreted using S. aureus/S. lugdunensis b

15 categorical agreement (CA) between Etest and BMD results across CLSI and EUCAST breakpoints.

16 gnosed either by imaging or by histology and BMD Z score was measured by dual-energy X-ray absorptiom

17 ble bedaquiline DST methods were MGIT960 and BMD using dry plates.

18 f the association, if any, between NAFLD and BMD.

19 or femoral neck (FN)-fracture prediction and BMD value prediction using 700 elderly Chinese Han subje

20 at ART initiation blunts bone resorption and BMD loss at key fracture-prone anatomical sites in treat

21 at ART initiation blunts bone resorption and BMD loss at key fracture-prone anatomical sites in treat

22 indicates an increase of bone retraction and BMD values and a decrease of BV/TV value in PER groups.

23 ction of osteoporotic fracture (OF) risk and BMD in Chinese populations, we built assessment models f

24 k-factor-based FRAX (CRF-FRAX) screening and BMD-based FRAX (BMD-FRAX) screening.

25 of individuals requiring CRF-FRAX tests and BMD-FRAX tests were reduced by 37% and 41%, respectively

26 A exon sequencing of two cell lines (TMD and BMD) derived from a mouse xenograft model.

27 um, and 25-hydroxyvitamin D), and annualized BMD reduction over a 8-year follow-up of 692 middle-aged

28 Areal BMD (aBMD) was measured at 0, 3, 9, and 15 months.

29 was percentage change from baseline in areal BMD by dual-energy x-ray absorptiometry at the total hip

30 We measured areal BMD (aBMD) by DXA, and distal radius and tibia bone micr

31 rcentage change from baseline in spine areal BMD (aBMD) at 15 months.

32 375,984 Icelandic samples (MAF = 0.03%, arm BMD P-value = 0.12, forearm fracture P-value = 0.005).

33 The Sensititre broth micro-dilution assay (BMD) tests multiple drugs quantitatively.

34 ) is a primary contributor to TDF-associated BMD decline in this age group.

35 aily RCE intake over 1 y potently attenuated BMD loss caused by estrogen deficiency, improved bone tu

36 EN RD16/0009) and Community of Madrid (B2017/BMD-3686 CIFRA2-CM).

37 were used to compare the differences between BMDs, obesity and sarcopenia related traits from differe

38 efined as lumbar spine BMD and/or total-body BMD z scores of -1 or lower or -2 or lower, respectively

39 to determine lumbar spine BMD and total-body BMD.

40 is study illustrated that the vertebral body BMD values of the patients with scoliosis were significa

41 and significantly improved LS and whole body BMD compared to participants on vitamin D/calcium supple

42 and significantly improved LS and whole body BMD compared to participants on vitamin D/calcium supple

43 Lumbar spine and whole body BMD z-scores remained below baseline 48 weeks off PrEP i

44 imilar improvements were seen for whole body BMD.

45 ificantly associated with reduced whole-body BMD Z scores in children and adolescents; however, the o

46 Both BMD concentrations had an immediate and lasting impact o

47 nocytochemistry revealed that nuclei of both BMD and splenic macrophages from wild type mice contain

48 andard cation-adjusted Mueller-Hinton broth (BMD) and iron-depleted cation-adjusted Mueller-Hinton br

49 stin well displayed a colistin MIC of >=4 by BMD, all were determined to be negative for the mcr-1 an

50 Colistin resistance determined by BMD was associated with lower mortality among patients w

51 The susceptibilities of all isolates by BMD were 72% (FDA), 75% (EUCAST) and 90% (CLSI).

52 non-glucose-fermenting GNB (50 isolates) by BMD (lyophilized panels; Sensititre; Thermo Fisher) and

53 elded MICs of 2 ug/ml by CBDE and 4 ug/ml by BMD.

54 d were susceptible to imipenem-relebactam by BMD.

55 Cefoxitin BMD led to 4.9% VMEs and 1.6% MEs.

56 Es, and 3.6% VMEs and 3.9% MEs for cefoxitin BMD.

57 ctively, compared to the results of colistin BMD.

58 CBDE was compared to colistin BMD using a collection of Gram-negative bacilli tested a

59 In contrast, BMD cells formed a spheroid with a smoother and more cir

60 ial total BMD (P = 0.02) and tibial cortical BMD (P = 0.03) at 12 mo postpartum than the placebo grou

61 One hundred and three had decreased BMD (61 with osteoporosis and 42 with osteopenia) and 70

62 Women over 58 years old with decreased BMD presented with a higher mean percentage of sites wit

63 one area, mineral content (BMC) and density (BMD), and higher cancellous bone volume fraction in lumb

64 ly correlated with low bone mineral density (BMD) (g/cm(2)), lumbar spine L2-L4 and femoral neck (T-s

65 riants associated with bone mineral density (BMD) after enriching the discovery cohort for loss-of-fu

66 n characterized by low bone mineral density (BMD) and an increased risk of fracture.

67 eradication of HCV on bone mineral density (BMD) and biomarkers of bone remodeling in HIV/HCV coinfe

68 Bone mineral density (BMD) and bone mineral content (BMC) Z scores were signif

69 rabecular and cortical bone mineral density (BMD) and content were assessed at the tibia and radius b

70 ers were compared with bone mineral density (BMD) and cortical bone thickness.

71 phy thoracic vertebral bone mineral density (BMD) and fracture prevalence among physically active Tsi

72 s) identified multiple bone mineral density (BMD) and fracture-associated loci.We conducted a study t

73 ssociation between low bone mineral density (BMD) and periodontitis in perimenopausal women is contro

74 adult ages to measure bone mineral density (BMD) at routine CT.

75 Derangement in bone mineral density (BMD) caused by glucocorticoid is well-known.

76 Background Bone mineral density (BMD) could be derived from CT localizer radiographs and

77 Bone mineral density (BMD) derived from cardiac CT may be used to determine fr

78 Little is known about bone mineral density (BMD) during pregnancy.

79 d 15-22 years who lost bone mineral density (BMD) during tenofovir disoproxil fumarate/emtricitabine

80 n D supplementation on bone mineral density (BMD) have yielded conflicting results.

81 GRFs) for fracture and bone mineral density (BMD) identified from people of European descent can help

82 er disease (NAFLD) and bone mineral density (BMD) in children or adolescents, but these have produced

83 ium supplementation on bone mineral density (BMD) in lactating women.

84 We aimed to evaluate bone mineral density (BMD) in patients with scoliosis by using quantitative co

85 for rehabilitation of bone mineral density (BMD) in people with Spinal Cord Injury (SCI).

86 d adolescents with low bone mineral density (BMD) may be at higher risk of osteoporosis and fractures

87 infection and with low bone mineral density (BMD) may be at higher risk of osteoporosis and fractures

88 Bone mineral density (BMD) measurement by dual-energy x-ray absorptiometry (DX

89 hy (QUS) in predicting bone mineral density (BMD) reduction in a population of Ugandan HIV-infected i

90 eases in hip and spine bone mineral density (BMD) than with either drug alone.

91 help measure thoracic bone mineral density (BMD) to identify individuals who have low BMD and a grea

92 als who share the same bone-mineral density (BMD) vary in their fracture risk, suggesting that micros

93 Bone mineral density (BMD) was measured using DXA.

94 e turnover markers and bone mineral density (BMD) were quantified at weeks 0, 12, 24, 48, 96, and 144

95 n areal and volumetric bone mineral density (BMD), bone microstructure and strength, fracture risk, a

96 tion; bone retraction, bone mineral density (BMD), bone volume/tissue volume (BV/TV) by micro-CT anal

97 bustly associated with bone mineral density (BMD), but not the precise localization of effector genes

98 , hip and lumbar spine bone mineral density (BMD), mental health score, fat and lean body mass, and s

99 l variation influences bone mineral density (BMD), obesity, and sarcopenia related traits in other co

100 n increase in fitness, bone mineral density (BMD), quality of life and a decrease of IBD induced stre

101 zole on bone turnover, bone mineral density (BMD), true fractional calcium absorption (TFCA), serum a

102 s with low versus high bone mineral density (BMD), we recovered methylation values of ~ 300 K CpGs in

103 outcome was total hip bone mineral density (BMD), with femoral neck BMD, lumbar spine BMD, and lumba

104 ference standard was a bone mineral density (BMD)-based Fracture Risk Assessment Tool (FRAX) score.

105 gnosed primarily using bone mineral density (BMD).

106 dy summary datasets of bone mineral density (BMD).

107 rily by measurement of bone mineral density (BMD).

108 by fracture and lower bone mineral density, BMD) is associated with subsistence task cessation.

109 mp2NLS(tm) mutant mice, bone marrow derived (BMD) macrophages and splenic macrophages were isolated f

110 lation reprogramming in bone marrow-derived (BMD) monocytes as early as 4 days of recovery from EHS a

111 < 5% (group B), and 21 of 34 (61%) developed BMD.

112 ration of bacitracin methylene disalicylate (BMD) to commercial turkeys for 14 weeks, and its effect

113 Borrelia miyamotoi disease (BMD) is a newly recognized borreliosis that is cotransmi

114 DXA BMD measurements were significantly associated (P < .01)

115 y (DMD) or milder Becker muscular dystrophy (BMD).

116 After 30 days of recovery from EHS, BMD monocytes exhibited an altered in vitro heat shock r

117 279,435 UK (MAF = 0.05%, heel bone estimated BMD P-value = 1.2 x 10(-16), any fracture P-value = 0.05

118 fracture loci, all associated with estimated BMD (eBMD), in ~1.2 million individuals.

119 In-feed BMD may cause bacterial metabolic shifts, leading to ben

120 GH treatment increased femur BMD and lean body mass but decreased the % fat measured

121 17 fracture-associated genes and 82 FN-BMD associated genes identified in people of European de

122 ults showed that, adding fracture GRF and FN-BMD GRF to the model with CRFs, the area under the recei

123 acture GRF and by the Model with CRFs and FN-BMD GRF, respectively, as compared to 65.5% in the Model

124 For BMD, cation-adjusted Mueller-Hinton broth (CAMHB) requir

125 ot provide clinically important benefits for BMD in lactating women.

126 ltiple linear regression model with CRFs for BMD prediction in Chinese.

127 l of concordance between CLSI and EUCAST for BMD testing and Etest was >95%.

128 that of the model with both CRFs and GRF for BMD prediction.

129 culosis clinical isolates were processed for BMD and whole genome sequencing.

130 re not significantly different from that for BMD, although they tended to be 1 to 2 dilutions higher.

131 ssociated with decreased ultradistal forearm BMD (P-value = 2.1 x 10(-18)), and increased osteoporosi

132 RAX (CRF-FRAX) screening and BMD-based FRAX (BMD-FRAX) screening.

133 40 mug and denosumab increases spine and hip BMD more than standard combination therapy.

134 ed to football appeared to have improved hip BMD and fewer hospital admissions.

135 fference was observed in change in total hip BMD, in favour of FG (0.007 g/cm2 [95% CI 0.004 to 0.013

136 had a small to moderate effect on total-hip BMD (WMD: 3.3%; 95% CI: 1.5%, 5.1%) but no effect on tot

137 d considerable discordance between AD and ID-BMD.

138 ted cation-adjusted Mueller-Hinton broth (ID-BMD), and agar dilution (AD) using standard Mueller-Hint

139 high error rates for AD in comparison to ID-BMD.

140 atment characteristics, correctly identified BMD status in most white adult survivors through age 40

141 Denosumab improved BMD and reduced the incidence of new radiographic verteb

142 The primary outcome was change in BMD (DeltaBMD) at the hip.

143 There was no difference in change in BMD over 12 mo between the 3 doses of vitamin D, suggest

144 Percentage change in BMD was pooled using random-effects models and reported

145 s not associated with significant changes in BMD nor biomarkers of bone remodeling in HIV/HCV-coinfec

146 ment had no significant effect on changes in BMD that occurred between 12-20 wk of gestation and 0-14

147 icant differences among groups in changes in BMD, PTH, serum or urine levels of minerals, or TFCA.

148 r attenuation of the anticipated decrease in BMD over 12 mo.

149 In-frame deletions in BMD and a DMD non-silent mutation (C3340Y) resulted in d

150 is of glucocorticoid- induced derangement in BMD.

151 as no significant geographical difference in BMD for males or females under the criteria of p-values

152 No significant difference in BMD values was found between idiopathic and congenital s

153 nitored regularly to track expected gains in BMD by serial DXA scans.

154 pharmacologic therapy with an improvement in BMD, or who have an incident fragility fracture on thera

155 n be reached whereby further improvements in BMD are not associated with further reductions in fractu

156 f metabolites were differentially present in BMD treated turkeys for at least one time point (q < 0.1

157 onse to bacterial supernatant are similar in BMD macrophages isolated from naive (uninfected) nBmp2NL

158 The aforementioned WMDs in BMD Z scores were independent of common clinical risk fa

159 viduals requiring screening tests, including BMD measurement, while maintaining a high sensitivity an

160 144 weeks after ZOL infusion, BMD did not change at the lumbar spine (P = .22) but dec

161 144 weeks after ZOL infusion, BMD did not change at the lumbar spine (p=0.22), but dec

162 ample (N = 19,705), and identified ten known BMD loci.

163 Low BMD was present in 51% and 45% of SJLIFE and Dutch parti

164 In ALGS, low BMD and BMC reference Z scores were explained by poor gr

165 lysis showed a clear association between low BMD and periodontitis, but only in women above 58 years

166 The model for low BMD included male sex (odds ratio [OR], 3.07), height (O

167 y (BMD) to identify individuals who have low BMD and a greater fracture rate.

168 Importantly, bone fragility is due to low BMD and deterioration in bone structure.

169 genes, CREBBP and EP300, contributed to low BMD following a literature review.

170 The model for very low BMD included male sex (OR, 3.28), height (OR, 0.95), wei

171 After adjusting for age and sex, very low BMD remained associated with any fracture (hazard ratio,

172 nadjusted Cox regressions analyses, very low BMD was association with a greater rate of any fracture

173 tch participants, respectively, and very low BMD was present in 20% and 10%, respectively.

174 Low and very low BMD were defined as lumbar spine BMD and/or total-body B

175 dated prediction models for low and very low BMD, using easily measured patient and treatment charact

176 e included, of whom 179 (12.0%) had very low BMD.

177 key biological pathways associated with low BMD after glucocorticoid treatment in asthmatics using g

178 199 genes significantly associated with low BMD in both childhood and adult asthmatics.

179 f over-45-year-old women with or without low BMD underwent lumbar spine and hip bone densitometry and

180 generally healthy perimenopausal women, low BMD was associated with clinical attachment level (CAL).

181 Lower BMD increases Tsimane fracture risk, but only for women,

182 cessation associated with fracture and lower BMD are substantial: ~397 lost kcals/day, with expected

183 ip fracture group was characterized by lower BMD, lower cortical thickness, lower relative adipose ti

184 do not easily explain Tsimane women's lower BMD.

185 an increases (95% confidence interval) in LS BMD over 48 weeks were significantly larger on alendrona

186 an increases (95% confidence interval) in LS BMD over 48 weeks were significantly larger on alendrona

187 in PHIV children and adolescents with low LS BMD, 48 weeks of alendronate was well-tolerated, showed

188 ts perinatally infected with HIV with low LS BMD, 48 weeks of alendronate was well-tolerated, showed

189 infected with HIV with low lumbar spine (LS) BMD (Z score < -1.5) were randomized to receive once-wee

190 nificant differences in whole-body or lumbar BMD Z scores between children/adolescents with and witho

191 each vertebral body from T12 to L5, and mean BMD was calculated for each case.

192 The mean BMD values of patients with scoliosis were significantly

193 edaquiline concentrations for the AP method, BMD (frozen or dry plates), and MGIT960, respectively.

194 bactam AST by reference broth microdilution (BMD) according to Clinical and Laboratory Standards Inst

195 Broth microdilution (BMD) and disk diffusion methods have been developed to d

196 proportion (AP) assay, broth microdilution (BMD) assay, and mycobacterial growth indicator tube (MGI

197 titute (CLSI) reference broth microdilution (BMD) for 99 isolates of Pseudomonas aeruginosa, 26 Acine

198 ffusion methods (DD) to broth microdilution (BMD) for AST of Gram-negative bacilli (GNB).

199 est compared to that of broth microdilution (BMD) for identifying colistin MICs.

200 ent results to those of broth microdilution (BMD) for imipenem-relebactam susceptibility testing usin

201 sents an alternative to broth microdilution (BMD) for performing antimicrobial susceptibility testing

202 disk diffusion (DD) and broth microdilution (BMD) methods for the detection of mecA-mediated beta-lac

203 ve to the gold standard broth microdilution (BMD) test (MIC(50) and MIC(90) of 1 and 1.5 mg/liter, re

204 cefoxitin and oxacillin broth microdilution (BMD), disk diffusion (DD), and PBP2a immunoassay, and th

205 Broth microdilution (BMD), macrodilution (MD), and agar dilution (AD) methods

206 nt (CoR) when tested by broth microdilution (BMD).

207 the capacity to perform broth microdilution (BMD).

208 ed by the gold standard broth microdilution (BMD).

209 hanges in serum and urine levels of mineral, BMD, PTH (all subjects), and TFCA (n = 30).

210 groups in serum or urine levels of minerals, BMD, or PTH at week 26.

211 Minimal BMD differences exist between Tsimane and American men,

212 The means +/- SDs of femoral neck BMD loss were -0.02 +/- 0.05 and 0.0 +/- 0.03 g/cm(2) fo

213 s comprised the dose effects on femoral neck BMD, falls, circulating calciotropic hormones, bone turn

214 one mineral density (BMD), with femoral neck BMD, lumbar spine BMD, and lumbar spine trabecular bone

215 but no effect on total body or femoral neck BMD.

216 I: 2.4, 26.7; P = .001) compared with normal BMD.

217 We assessed genetic determinants of BMD as estimated by heel quantitative ultrasound in 426,

218 nsitive enough for confirming a diagnosis of BMD but that SCID mouse inoculation could be a useful co

219 racy was defined as the measurement error of BMD (DeltaBMD), and precision was defined as the coeffic

220 e fracture prediction in Chinese; and GRF of BMD from people of European descent cannot help improve

221 in Chinese perhaps partially because GRF of BMD from people of European descent may not contribute t

222 of widened, unstable bones, independently of BMD.

223 Measurements of BMD were performed by QCT analysis for each vertebral bo

224 the past half century to provide measures of BMD and bone microarchitecture for the purposes of clini

225 pose To assess the accuracy and precision of BMD measurement using two localizer radiographs obtained

226 to a large genome wide association study of BMD.

227 nce of the new P/T Etest compared to that of BMD following U.S. Food and Drug Administration (FDA) an

228 all other isolates were in CA with those of BMD.

229 horts to evaluate geographical variations of BMD and body composition.

230 terations continued even after withdrawal of BMD.

231 Effects of teriparatide and denosumab on BMD and fractures are unclear (very low SOE), and these

232 (600/1000 mg/d) had no significant effect on BMD at the lumbar spine (WMD: 0.74%; 95% CI: -0.10%, 1.5

233 and fractures due to the lifelong effect on BMD observed in the study.

234 r studies which reported positive effects on BMD.

235 no significant geographical effect found on BMD.

236 Effects of osteoporosis medications on BMD, fracture risk, and safety among patients with CKD a

237 d the effect of vitamin D supplementation on BMD at the hip, using dual-energy X-ray absorptiometry.

238 en and men at least 50 y old with osteopenic BMD warrant pharmacologic treatment if they have a FRAX-

239 fragility fracture, or with an osteoporotic BMD should also be treated.

240 Oxacillin BMD testing by current Clinical and Laboratory Standards

241 Oxacillin BMD using S. aureus/S. lugdunensis breakpoints yielded t

242 pseudintermedius/S. schleiferi and oxacillin BMD and cefoxitin DD tests using the CoNS breakpoints re

243 Likewise, oxacillin BMD and cefoxitin DD tests using the coagulase-negative

244 In the animal phantom, BMDs from both CT systems were compared with those from

245 ed in statistically significant lower radial BMD; tibial BMD was significantly lower only with the 10

246 nary creatinine ratio (uRBP/uCr) and reduced BMD.

247 rbirth intervals are associated with reduced BMD for women.

248 of conventionally prepared frozen reference BMD panels for a number of drugs, including aztreonam-av

249 was performed using custom frozen reference BMD panels prepared in-house at the Centers for Disease

250 by CBDE should be confirmed by the reference BMD method, and isolates with MICs of >=2 ug/ml should b

251 +/- 0.4% of baseline weight), 6-mo regional BMD estimates were similar to those in the WS group (all

252 on required CRF-FRAX tests, and 37% required BMD-FRAX tests to achieve this accuracy.

253 and bone mineral density genetic risk score (BMD-GRS) modify the association between the intake of ca

254 tabine preexposure prophylaxis (PrEP) showed BMD recovery 48 weeks following PrEP discontinuation.

255 +/- 0.006 g/cm2, P <0.001), and lumbar spine BMD (0.025 +/- 0.007 g/cm2, P = 0.001).

256 ray absorptiometry to determine lumbar spine BMD and total-body BMD.

257 nd very low BMD were defined as lumbar spine BMD and/or total-body BMD z scores of -1 or lower or -2

258 nces were observed in change in lumbar spine BMD or lean body mass.

259 At 48 weeks, lumbar spine BMD with ZOL was 11% higher than placebo (n = 60; P < .0

260 At 48 weeks, lumbar spine BMD with ZOL was 11% higher than placebo (n=60; p<0.001)

261 y (BMD), with femoral neck BMD, lumbar spine BMD, and lumbar spine trabecular bone score (TBS) as sec

262 African Americans lost more spine BMD than did Caucasians (-0.04 +/- 0.04 compared with -0

263 ne total hip, femoral neck, and lumbar spine BMDs were 1.016 +/- 0.160, 0.941 +/- 0.142, and 1.287 +/

264 We prospectively assessed standardized BMD (sBMD) at the lumbar spine and femoral neck, World H

265 height-adjusted and weight-adjusted subtotal BMD and BMC Z scores were negatively correlated with TB

266 ve computed tomography (QCT) and compare the BMD of idiopathic and congenital scoliosis patients.

267 eptibility breakpoint of 0.12 mug/ml for the BMD method and WHO interim CCs of 1 mug/ml for MGIT and

268 MICs were 1 doubling dilution apart from the BMD MICs.

269 served and significantly associated with the BMD Z score in adult asthmatics as well.

270 gene modules significantly related with the BMD Z score in childhood asthmatics and tested if these

271 With some drug therapies, BMD targets can be reached whereby further improvements

272 sociation between fracture rate and thoracic BMD derived from cardiac CT.

273 tically significant lower radial BMD; tibial BMD was significantly lower only with the 10 000 IU per

274 offers a convenient alternative approach to BMD methods for cefiderocol AST, with the exception of A

275 le of European descent may not contribute to BMD prediction in Chinese.

276 Disk diffusion performed poorly relative to BMD under CLSI (CA, 55%) and EUCAST (CA, 36%) guidelines

277 tion and Etest yielded comparable results to BMD for imipenem-relebactam.

278 Trabecular and total BMD at the tibia trended toward higher values (P < 0.06)

279 nificantly greater increases in radial total BMD (P = 0.02) and tibial cortical BMD (P = 0.03) at 12

280 a shift in disease phenotype from DMD toward BMD.

281 8, 0.93), as well as trochanteric trabecular BMD combined with neck cortical thickness (model B2) (AU

282 nly with total hip (P = 0.01) and trochanter BMD (P = 0.007) in postmenopausal women.

283 Tsimane BMD is lower versus Americans, but only for women, contr

284 Using BMD as the gold standard, our genotypic resistance predi

285 Hazard ratios were assessed by using BMD categorized as very low (<80 mg/cm(3)), low (80-120

286 ant group x time interactions for volumetric BMD.

287 group with mean percent change in volumetric BMD of -1.2% (400 IU group), -2.4% (4000 IU group), and

288 In all participants, volumetric BMD of three thoracic vertebrae was measured by using qu

289 At trial end, radial volumetric BMD was lower for the 4000 IU group (-3.9 mg HA/cm3 [95%

290 Tibial volumetric BMD differences from the 400 IU group were -1.8 mg HA/cm

291 Co-primary outcomes were total volumetric BMD at radius and tibia, assessed with high resolution p

292 emoral neck, World Health Organization (WHO) BMD categories at both sites, and plasma concentrations

293 an colistin well, categorical agreement with BMD was 92.7%, and the very major error rate was 10.7%.

294 Surprisingly, categorical agreement with BMD was only 47.6%, 57.1%, and 44.6% for the three metho

295 ve, DASH was more positively associated with BMD than AHEI or MeDS in postmenopausal women not taking

296 genes including CRP, was not associated with BMD.

297 CpGs that are significantly associated with BMD.

298 The MEPE LoF association with BMD and fractures was further evaluated in 279,435 UK (M

299 scores) and their individual components with BMD and osteoporosis were tested with ANCOVA and logisti

300 n is associated with ALM and QS but not with BMD.